Compare Merck & Co., Inc. (MRK) vs Oxford Lane Capital Corp (OXLC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Oxford Lane Capital Corp — how do they compare? Merck & Co., Inc. trades at $133.62 (market cap $321.77B), while Oxford Lane Capital Corp trades at $9.54 (market cap $909.61M). The key difference: Merck & Co., Inc. is far larger — about 353.7× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays the higher dividend (25.76%). Which is the better fit depends on your goals.
| MRK | OXLC | |
|---|---|---|
Market Cap | $321.77B | $909.61M |
Sector | Health | Financials |
52-Week High | $131.84 | $18.75 |
52-Week Low | $77.60 | $8.15 |
Enterprise Value | $368.53B | — |
Dividend Yield | 2.61% | 25.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck & Co. (MRK) trades at $133.64, up 2.09% today, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported solid earnings beats in recent quarters, with Q3 2026 EPS expected at $2.27. Revenue for 2025 reached $65.01B, and net income was $18.25B, though the P/E ratio of 104.34 suggests high valuation expectations. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
Outlook: MRK's growth is supported by strategic acquisitions and a dominant oncology franchise, but risks include high valuation multiples and competitive pressures. The consensus price target of $140.36 implies modest upside, with 68% of analysts rating it a Buy. Investors should monitor execution on the Terns integration and Q3 earnings results for catalysts.
OXLC trades at $9.51, up 2.59% today, with a bullish technical signal from moving averages but a neutral RSI. The stock shows mixed fundamentals: a low P/B of 0.88 suggests undervaluation, but negative ROE and ROA highlight profitability challenges. Recent earnings misses and a sharp revenue decline in 2026 contrast with consistent $0.20 monthly dividends. News sentiment is divided, with some highlighting high yield opportunities and others warning of NAV erosion and unsustainable payouts.
The outlook is cautious due to earnings volatility and high yield sustainability concerns. Opportunities include deep discount to book value and analyst buy ratings, but risks involve persistent net income losses, negative cash flow from operations, and potential dividend cuts if NAV declines continue.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Oxford Lane Capital Corp
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →
